Clinical Trials Browser

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07488923 2026-04-01

SPECTRAL-1

Phase 1 Not yet recruiting

110 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT07377487 2026-03-30

INDIGO

Phase NA Recruiting

51 enrolled

EndocrineGastrointestinalNET

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06041516 2026-03-27

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Phase 1 Recruiting

70 enrolled

CNSEndocrineNET

Neuroblastoma, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT07129252 2026-03-10

BRAVESST2

Phase 1/2 Recruiting

150 enrolled

EndocrineNET

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07458906 2026-03-09

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Phase NA Recruiting

60 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT04471727 2026-02-24

MK-6070-001

Phase 1/2 Active not recruiting

232 enrolled

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

29 enrolled

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06937905 2026-02-11

TARLANEC

Phase 3 Recruiting

129 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT07080242 2026-02-09

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Phase 1 Recruiting

120 enrolled

Endocrine

Neoplasm Metastasis, Carcinoma, Neuroendocrine

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

208 enrolled

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Clinical Trials

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

LCNEC-ALPINE

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

DeLLight

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

TRIDENT-1

SPECTRAL-1

INDIGO

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

BRAVESST2

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

MK-6070-001

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

TARLANEC

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer